Literature DB >> 7606337

Functional dopamine D2 receptors on rat vagal afferent neurones.

A J Lawrence1, E Krstew, B Jarrott.   

Abstract

1. In the present study in vitro electrophysiology and receptor autoradiography were used to determine whether rat vagal afferent neurones possess dopamine D2 receptors. 2. Dopamine (10-300 microM) elicited a temperature- and concentration-dependent depolarization of the rat isolated nodose ganglion preparation. When applied to the tissue 15 min prior to agonist, raclopride (10 microM), clozapine (10 microM) or a mixture of raclopride and clozapine (10 microM each) all produced a threefold parallel shift to the right of the dopamine concentration-response curve. In contrast, SCH 23390 (100 nM), phentolamine and propranolol (1 microM each) failed to antagonize the dopamine-mediated depolarization. 3. [125I]-NCQ 298 (0.5 nM), a D2 selective radioligand, bound topographically to sections of rat brainstem. Densitometric quantification of autoradiograms revealed 93.8 +/- 0.5% specific binding of this salicylamide radioligand, as determined by raclopride (10 microM, n = 10 animals). Binding was highest in the nucleus tractus solitarius (NTS), particularly the medial and gelatinous subnuclei. In addition, specific binding was also observed in the interpolar spinal trigeminal nucleus and the inferior olive. 4. Unilateral nodose ganglionectomy caused a 36.6 +/- 3.0% reduction in specific binding in the denervated NTS compared to the contralateral NTS. Furthermore, the loss of binding was confined to the dorsal aspect of the medial subnucleus of the NTS. Sham surgery had no effect on the binding of [125I]-NCQ 298 in rat brainstem. 5. The present data provide evidence for the presence of functionally relevant dopamine D2 receptors on both the soma and central terminals of rat vagal afferent neurones. In addition, the majority of D2 receptors in the rat NTS appear to be located postsynaptically with respect to vagal terminals, and are presumably located either on ascending glossopharyngeal terminals, descending terminals from higher brain regions or on neuronal cell bodies within the NTS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606337      PMCID: PMC1510284          DOI: 10.1111/j.1476-5381.1995.tb13352.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Involvement of neurotransmitters in the nucleus tractus solitarii in cardiovascular regulation.

Authors:  P L van Giersbergen; M Palkovits; W De Jong
Journal:  Physiol Rev       Date:  1992-07       Impact factor: 37.312

2.  Expression of D2 dopamine receptor mRNA in the arterial chemoreceptor afferent pathway.

Authors:  M F Czyzyk-Krzeska; E E Lawson; D E Millhorn
Journal:  J Auton Nerv Syst       Date:  1992-11

Review 3.  Arterial baroreceptor reflex: its central and peripheral neural mechanisms.

Authors:  M Kumada; N Terui; T Kuwaki
Journal:  Prog Neurobiol       Date:  1990       Impact factor: 11.685

Review 4.  Molecular diversity of the dopamine receptors.

Authors:  O Civelli; J R Bunzow; D K Grandy
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

5.  NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.

Authors:  H Hall; T Högberg; C Halldin; C Köhler; P Ström; S B Ross; S A Larsson; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Electrophysiological responses of angiotensin peptides on the rat isolated nodose ganglion.

Authors:  R E Widdop; E Krstew; B Jarrott
Journal:  Clin Exp Hypertens A       Date:  1992

7.  Baroreceptor reflex inhibition induced by the stimulation of serotonin3 receptors in the nucleus tractus solitarius of the rat.

Authors:  N Merahi; H S Orer; A M Laporte; H Gozlan; M Hamon; R Laguzzi
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

8.  Transmitter diversity in carotid body afferent neurons: dopaminergic and peptidergic phenotypes.

Authors:  J C Finley; J Polak; D M Katz
Journal:  Neuroscience       Date:  1992-12       Impact factor: 3.590

9.  Presence of functional vasopressin V1 receptors in rat vagal afferent neurones.

Authors:  X Gao; P A Phillips; R E Widdop; D Trinder; B Jarrott; C I Johnston
Journal:  Neurosci Lett       Date:  1992-09-28       Impact factor: 3.046

10.  Dual responses of carotid chemosensory afferents to dopamine in the newborn kitten.

Authors:  F Marchal; A Bairam; P Haouzi; J M Hascoet; J P Crance; P Vert; S Lahiri
Journal:  Respir Physiol       Date:  1992-11
View more
  5 in total

1.  Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination.

Authors:  J Drago; P Padungchaichot; J Y Wong; A J Lawrence; J F McManus; S H Sumarsono; A L Natoli; M Lakso; N Wreford; H Westphal; I Kola; D I Finkelstein
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

2.  The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.

Authors:  A J Lawrence; E V Krstew; F M Dautzenberg; A Rühmann
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 3.  Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting.

Authors:  Nissar A Darmani
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-03

4.  Time-dependent assessment of stimulus-evoked regional dopamine release.

Authors:  Rachel N Lippert; Anna Lena Cremer; Sharmili Edwin Thanarajah; Clio Korn; Thomas Jahans-Price; Lauren M Burgeno; Marc Tittgemeyer; Jens C Brüning; Mark E Walton; Heiko Backes
Journal:  Nat Commun       Date:  2019-01-18       Impact factor: 14.919

5.  Dopamine D2-Subtype Receptors Outside the Blood-Brain Barrier Mediate Enhancement of Mesolimbic Dopamine Release and Conditioned Place Preference by Intravenous Dopamine.

Authors:  J Daniel Obray; Christina A Small; Emily K Baldwin; Eun Young Jang; Jin Gyeom Lee; Chae Ha Yang; Jordan T Yorgason; Scott C Steffensen
Journal:  Front Cell Neurosci       Date:  2022-07-12       Impact factor: 6.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.